Javelin Pharmaceuticals names new vice president of clinical research

Dr Lang comes from Novartis, where he was most recently the global head of clinical R&D for analgesia for its consumer health division. In that capacity, Dr Lang was responsible for the design and implementation of the clinical strategy for its global analgesics franchise.

Dr Lang has received his medical degree at Ben Gurion University of the Negev in Beer Sheba, Israel and completed an acute and chronic pain fellowship at Emory University Medical School.

Martin Driscoll, CEO of Javelin, said: “I am pleased to welcome Eric to the Javelin team. Eric’s successful clinical and regulatory experience in analgesics, including Voltaren sodium gel, should greatly benefit Javelin.

“Javelin plans to file two high quality new drug applications in the US later next year, one is for Dyloject an injectable form of diclofenac sodium for acute treatment of pain. Eric will report to Daniel Carr, our president and chief medical officer.”